FDA Provides Accelerated Approval of Talvey for Multiple Myeloma

TUESDAY, Aug. 15, 2023 -- The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma. The accelerated approval is for individuals who have received at least four prior...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news